1Q Preview: Japan Policy Worries, Indian Mixed Bag
This article was originally published in PharmAsia News
As major companies start to release their quarterly results over the next few weeks, PharmAsia News takes a market-by-market look at some of the key expectations, challenges and policy factors likely to have the biggest influence on Asia’s major corporate players.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.